Ubix Therapeutics

Ubix Therapeutics Inc. develops novel anticancer drugs based on a targeted proteolysis-targeting chimera (PROTAC) platform technology. PROTAC is a powerful next-generation inhibitor technology capable of targeting previously "undruggable" disease-related targets. The company creates innovative cancer immunotherapies based on a thorough understanding of the human immune system and target proteins. In doing so, they aim to contribute to extending life expectancy and improving quality of life.